updated 5/5/2011 7:16:12 AM ET 2011-05-05T11:16:12

HAIFA, Israel, May 5, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR), announced today that over the next two months, company executives will be presenting at four leading industry events. The presentations follow the completion of six-month follow-up on patients treated with the Company's Critical Limb Ischemia therapeutic, PLX-PAD.

"As part of our ongoing clinical, scientific and financial progress, we are pleased to be invited to present at a variety of financial and scientific conferences," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "These presentations will enable us to discuss the competitive advantages of our platform, as well as our planned product portfolio, with a number of strategic target audiences."

Phase I clinical trials suggest that Pluristem's placenta-derived cell therapy, PLX-PAD, is safe, improves quality of life, and is potentially effective in treating patients and reducing amputation rate in those suffering from Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD). Among the 27 patients treated with PLX-PAD, no mortality events and only one amputation were recorded, representing a 3.7% amputation rate. This represents a 75% reduction in amputation rate compared to historical data, which varies between 20-40%.

Over the next two months, Pluristem will be presenting at the following conferences:

Oppenheimer 12th Annual Israeli Conference
May 15, 2011, Tel-Aviv, Israel
Zami Aberman, Chairman & CEO, will participate in a
Q&A Session with Oppenheimer's Analyst
2:30 – 3:30 pm, Hall #3
 
17th Annual Meeting of the International Society for Cellular Therapy
May 18-21, Rotterdam, The Netherlands
Frida Grynspan, PhD, VP Research and Development, will present:

"Commercialization strategies for the development of PLX-PAD; Placental

expanded adherent stromal cells, an "off the shelf" product"
Saturday, May 21 from 1:15 to 2:45 pm
 
BioMed Israel 2011 
May 23-25, Tel Aviv, Israel
Zami Aberman, Chairman& CEO, will present:
"Placental Derived Adherent Stromal Cells for the Treatment of Critical Limb

Ischemia and Heart Diastolic Dysfunction"
Company Presentations
Monday, May 23 between 12:55 - 1:35 pm, Hall D
 
Company Presentations, Biopharma
Tuesday, May 24 from 5:10pm to 5:30 pm, Hall B
 
2011 Bio International Convention - June 27-30, Washington, DC.
Zami Aberman, Chairman & CEO, will participate in the Israel delegation and

will present at the Israel Pavilion - Booth 3737, Hall A
 
The 2011 AOSSM Annual Meeting -- July 7-10, San Diego, California.
Dr. William R. Prather, Sr. VP Corporate Development, will participate in the

event and meet with interested parties at the Company's booth in the exhibition area.

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching prior to administration. Data from two phase I studies indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage Peripheral Artery Disease. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage, when administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically.   

Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team.

For more information visit www.pluristem.com , the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.

The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we speak about the competitive advantages of our platform, or when we say that Phase I clinical trials suggest that our placenta-derived cell therapy, PLX-PAD, is safe, improves quality of life, and is potentially effective in treating patients and reducing amputation rate in those suffering from Critical Limb Ischemia (CLI), or when we say that Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically, or when we say that we have a strong patent portfolio. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.
         William Prather R.Ph., M.D.
         Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com

         Daya Lettvin
         Director Investor & Media Relations
         +972-54-674-5580
         daya@pluristem.com

         Media Contact:

         Matthew Krieger
         Ruder Finn - for Pluristem
         +972-54-467-6950
         matthew@ruderfinn.co.il

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.96%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.66%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.21%
Cash Back Cards 17.73%
17.70%
Rewards Cards 17.00%
16.96%
Source: Bankrate.com